Which pharmaceutical company produces Ribociclib and an introduction to its global launch and supply?

Ribociclib is an oral small molecule CDK4/6 inhibitor, mainly used for the treatment of HR positive, HER2 negative advanced or metastatic breast cancer. The drug is developed and produced by Novartis (Novartis) and is one of the important drugs in the field of CDK4/6 targeted therapy. By selectively inhibiting cyclin-dependent kinases 4 and 6, ribociclib can block tumor cells from entering the G1 phase into the S phase, thereby inhibiting tumor cell proliferation and delaying disease progression.

In the domestic market, the original drug Ribociclib has been officially launched and included in the national medical insurance system. The commonly used specifications are 200mg*63 tablets, and each box sells for about more than 4,000 yuan. Its launch provides highly effective targeted therapy options for domestic patients with HR-positive and HER2-negative breast cancer. It is especially suitable for the treatment of patients with advanced breast cancer in combination with aromatase inhibitors or fulvestrant. Its clinical application has gradually become popular, and medical insurance reimbursement has also reduced the financial burden of patients.

In overseas markets, the original drugs of ribociclib are mainly European and Indian versions. Common specifications of the European version include 200mg21 tablets, 200mg42 tablets and 200mg63 tablets may be sold for more than 20,000 yuan per box; while the price of the original Indian version is relatively low, about more than 2,000 yuan per box, but the price may fluctuate due to exchange rates and regional policies. In addition, a number of generic drugs have appeared on the market in overseas markets, such as 200mg21 tablets produced by Lucius Pharmaceuticals in Laos. Each box sells for about more than 1,000 yuan. The ingredients of the two drugs are basically the same, providing more accessible options for patients in different regions.

In general, ribociclib, as a CDK4/6 inhibitor, has a relatively complete global supply. Domestic patients can purchase original drugs through medical insurance, while overseas patients can choose from European versions, Indian versions and generic drugs, with obvious price differences. Whether it is an original drug or a generic drug, its ingredients and efficacy are basically the same. However, in the specific medication process, it is still necessary to make a reasonable selection based on local medical insurance policies, supply channels and the patient's own conditions to ensure continuity of treatment and economic affordability.

Keyword tags: ribociclib,CDK4/6inhibitor, breast cancer, manufacturer, global supply

Reference materials:https://go.drugbank.com/drugs/DB11730